Posts by Lipika Goyal, MD
-
Futibatinib Efficacious for FGFR2 Fusion/Rearrangement Positive Intrahepatic Cholangiocarcinoma in Phase 2 Multinational Trial
Lipika Goyal, MD, MPhil and colleagues have reported futibatinib efficacy and safety data from the multinational phase 2 FOENIX-CCA2 trial, which led to accelerated FDA approval of the drug for patients who have advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions or rearrangements.
Biography
Lipika Goyal, MD, is a physician-investigator in the Mass General Cancer Center, a consultant in Hematology-Oncology at Massachusetts General Hospital, and an assistant professor of Medicine at Harvard Medical School.
Mass General Brigham Cancer Institute
Mass General Brigham Cancer Institute unites leading experts and resources across our academic medical centers, making it one of the nation’s top providers of cancer care.